Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
Main Authors: | Kumar Anshuman, Dhanashree Ratra |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Ophthalmology |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2019;volume=67;issue=7;spage=1119;epage=1120;aulast=Anshuman |
Similar Items
-
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
by: Sumit Randhir Singh, et al.
Published: (2019-01-01) -
Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
by: Parveen Sen, et al.
Published: (2016-01-01) -
Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy
by: Sheng-Chu Chi, et al.
Published: (2021-02-01) -
AFLIBERCEPT IN TREATMENT OF RESISTANT POLYPOID CHOROIDAL VASCULOPATHY: SHORT-TERM RESULTS
by: E. K. Pedanova, et al.
Published: (2017-12-01) -
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
by: Miura M, et al.
Published: (2013-08-01)